AMGN Jan 2025 200.000 call
| Previous Close | 72.17 |
| Open | 72.17 |
| Bid | 81.30 |
| Ask | 84.30 |
| Strike | 200.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 72.17 - 72.17 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 486 |
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- GuruFocus.com
Amgen Inc (AMGN) Q1 2024 Earnings: Aligns with EPS Projections Amid Revenue Growth and Challenges
Insight into Amgen's Financial Performance and Future Outlook
BloombergAmgen Soars After CEO Gives Update on Experimental Obesity Drug
(Bloomberg) -- Amgen Inc.’s shares soared in late trading after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesBiden Calls Ally Japan ‘Xenophobic’ Along With China, RussiaUS and Saudis Near Defense
